Online inquiry

IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8488MR)

This product GTTS-WQ8488MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGAL gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001114380.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3683
UniProt ID P20701
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8488MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13345MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ6729MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DS 1024
GTTS-WQ14004MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3500
GTTS-WQ7105MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ22MR IVTScrip™ mRNA-Anti-S, 2130(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 2130
GTTS-WQ4573MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986004
GTTS-WQ6675MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ3731MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-1093884
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW